NCIt definition : A bispecific antibody targeting Delta-like ligand 4 (DLL4) and vascular endothelial
growth factor A (VEGF-A), with potential anti-angiogenic and antineoplastic activities.
Upon administration, anti-DLL4/anti-VEGF-A bispecific antibody CTX-009 simultaneously
targets, binds to and blocks DLL4 and VEGF-A. This prevents the activation of DLL-4/Notch-
and VEGF-A/VEGF receptor (VEGFR)-mediated signaling pathways, which play key roles
in angiogenesis and tumor vascularization. This prevents angiogenesis and may halt
tumor cell proliferation. Activation of Notch receptors by DLL4 stimulates proteolytic
cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated
to the nucleus and mediates the transcriptional regulation of a variety of genes involved
in vascular development. The expression of DLL4 is highly restricted to the vascular
endothelium; DLL4/Notch signaling is required for the development of functional tumor
blood vessels. VEGF-A is upregulated in a variety of cancer cell types and plays a
crucial role in angiogenesis.;
Molecule name : ES-104; CTX 009; ES 104; CTX-009; ABL 001; TR 009; ABL-001; NOV1501;
Semantic type(s)